Abstract
The incidence of cough in children receiving antihypertension therapy with angiotensin-converting enzyme inhibitors (ACEis) or angiotensin receptor blockers (ARBs) is unknown. We analyzed patient-level data from eight randomized trials for the treatment of pediatric hypertension, six of them involving ACEis and two involving ARBs. The incidence of cough in children receiving ACEis (reported cough, 3.2%) was similar to that in children receiving ARBs (reported cough, 1.8%) (P = 0.34). Reports of cough were lower in children than in adults.
Publication types
-
Comparative Study
-
Research Support, N.I.H., Extramural
-
Research Support, U.S. Gov't, Non-P.H.S.
MeSH terms
-
Adolescent
-
Adult
-
Angiotensin II Type 1 Receptor Blockers / adverse effects*
-
Angiotensin II Type 1 Receptor Blockers / therapeutic use
-
Angiotensin-Converting Enzyme Inhibitors / adverse effects*
-
Angiotensin-Converting Enzyme Inhibitors / therapeutic use
-
Child
-
Cough / chemically induced*
-
Cough / epidemiology
-
Female
-
Humans
-
Hypertension / drug therapy*
-
Incidence
-
Male
-
Prevalence
-
Randomized Controlled Trials as Topic
Substances
-
Angiotensin II Type 1 Receptor Blockers
-
Angiotensin-Converting Enzyme Inhibitors